HBOX Therapies

Executive Summary

HBOX Therapies, a German medical device company founded in 2021, is developing next-generation extracorporeal gas exchange systems for acute respiratory failure. The company's compact, efficient, and user-friendly devices aim to address the limitations of current ECMO and ventilatory support technologies, offering safer and smarter respiratory support. By focusing on portability and ease of use, HBOX hopes to expand access to advanced respiratory care in hospitals and potentially pre-hospital settings. The technology is based on proprietary membrane and flow design, allowing for lower priming volumes, reduced blood trauma, and enhanced oxygen transfer efficiency. While still in early development, HBOX's platform could transform the management of acute respiratory distress syndrome (ARDS) and other critical care conditions, potentially reducing complications and improving patient outcomes. The company is currently seeking funding to advance its prototype through preclinical testing and toward first-in-human studies.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Round40% success
• Q2 2027Preclinical Proof-of-Concept Data Release50% success
• TBDFirst-in-Human Study Initiation20% success